[Lu177]-PNT-2002

N/A

Report date: 2025/11/19 17:58:27
NME

Base Information

Drug Name[Lu177]-PNT-2002
Drug Alias NamePNT-2002[Lu-177]-PNT-2002177Lu-PNT2002[Lu-177]-PSMA-I&T177Lu-PSMA-I&T
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionIonising radiation emittersProstate-Specific Membrane Antigen modulators
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsCarcinoma, Renal Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesScintomics
China Registration ClassN/A

Develop Information

Active CompaniesPDRadiopharma IncPeptiDream IncLawson Health Research Institute +[6] 
Inactive CompaniesProgenics Pharmaceuticals Inc
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsCarcinoma, Renal CellCarcinoma, Adenoid Cystic

Other Information

ATC CodeN/A
Related LinksN/A